Contents

Search

binimetinib/encorafenib

FDA approved June 2018 Indications: - treatment of patients with unresectable or metastatic BRAF V600E or V600K mutation-positive melanoma Dosage: - binimetini 15 mg, encorafenib 50-75 mg PO Adverse effects: - increased serum GGT - increased serum creatine kinase - hypertension Mechanism of action: - selective inhibitor of MEK (binimetini) - BRAF inhibitor (encorafenib)

General

antineoplastic combination (combination chemotherapy)

References

  1. FDA DRug Approvals. June 27, 2018 FDA approves encorafenib and binimetinib in combination for unresectable or metastatic melanoma with BRAF mutations. https://www.fda.gov/Drugs/InformationOnDrugs/ApprovedDrugs/ucm611981.htm
  2. Dummer R, Ascierto PA, Gogas HJ et al Encorafenib plus binimetinib versus vemurafenib or encorafenib in patients with BRAF-mutant melanoma (COLUMBUS): a multicentre, open-label, randomised phase 3 trial. Lancet Oncol. 2018 May;19(5):603-615. PMID: 29573941

Components

binimetinib encorafenib (Mektovi)